Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Interleukin 13 (IL13) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Interleukin 13 (IL13) Products under Development by Stage of Development | 8 | 1 |
| Interleukin 13 (IL13) Products under Development by Therapy Area | 9 | 1 |
| Interleukin 13 (IL13) Products under Development by Indication | 10 | 1 |
| Interleukin 13 (IL13) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Interleukin 13 (IL13) Products under Development by Companies | 13 | 2 |
| Interleukin 13 (IL13) Products under Development by Universities/Institutes | 15 | 2 |
| Interleukin 13 (IL13) Therapeutics Assessment | 17 | 6 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 1 |
| Assessment by Route of Administration | 19 | 2 |
| Assessment by Molecule Type | 21 | 2 |
| Interleukin 13 (IL13) Companies Involved in Therapeutics Development | 23 | 7 |
| Celgene Corporation | 23 | 1 |
| Delenex Therapeutics AG | 24 | 1 |
| F. Hoffmann-La Roche Ltd. | 25 | 1 |
| MedImmune, LLC | 26 | 1 |
| Neovacs SA | 27 | 1 |
| Novartis AG | 28 | 1 |
| Sanofi | 29 | 1 |
| Interleukin 13 (IL13) Drug Profiles | 30 | 15 |
| (dectrekumab + VAK-694) Drug Profile | 30 | 1 |
| dectrekumab Drug Profile | 31 | 2 |
| lebrikizumab Drug Profile | 33 | 3 |
| MEDI-7836 Drug Profile | 36 | 1 |
| Monoclonal Antibody to Inhibit IL-4 and IL-13 for Atopic Dermatitis Drug Profile | 37 | 1 |
| RPC-4046 Drug Profile | 38 | 2 |
| SAR-156597 Drug Profile | 40 | 1 |
| Small Molecules to Inhibit IL-13 for Ulcerative Colitis Drug Profile | 41 | 1 |
| tralokinumab Drug Profile | 42 | 2 |
| Vaccine to Target Interleukin 4 and Interleukin 13 for Allergies Drug Profile | 44 | 1 |
| Interleukin 13 (IL13) Dormant Projects | 45 | 2 |
| Interleukin 13 (IL13) Discontinued Products | 47 | 1 |
| Interleukin 13 (IL13) Featured News &Press Releases | 48 | 7 |
| Feb 29, 2016: Roche provides update on two identical phase III studies of lebrikizumab in people with severe asthma | 48 | 1 |
| Oct 03, 2014: Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis | 48 | 1 |
| Aug 14, 2014: AstraZeneca advances tralokinumab to Phase III in severe asthma | 49 | 1 |
| May 12, 2014: AstraZeneca to present respiratory data on tralokinumab at ATS 2014 International Conference | 49 | 2 |
| Mar 05, 2014: Roche's lebrikizumab phase IIb data show reduction of asthma attack rates and improvement of lung function in adult patients with severe uncontrolled asthma | 51 | 1 |
| Aug 04, 2011: Roche s Investigational Treatment For Asthma Meets Primary Endpoint In Phase II Study | 52 | 1 |
| Apr 15, 2008: MedImmune Advances Asthma Program With Start Of A Phase 2 Trial In Europe And Australia And First U.S.-Based Clinical Trial For Antibody Targeting IL-13 | 53 | 1 |
| Mar 18, 2008: MedImmune Advances Clinical Development Of Antibody Targeting Interleukin-9 In Patients With Asthma | 54 | 1 |
| May 25, 2005: Preclinical Data Support Link Between IL-9 And Airway Hyper-responsiveness Associated With Asthma | 54 | 1 |
| Appendix | 55 | 2 |
| Methodology | 55 | 1 |
| Coverage | 55 | 1 |
| Secondary Research | 55 | 1 |
| Primary Research | 55 | 1 |
| Expert Panel Validation | 55 | 1 |
| Contact Us | 55 | 1 |
| Disclaimer | 56 | 1 |